Investment Analysts’ Weekly Ratings Changes for Ligand Pharmaceuticals (LGND)

Several brokerages have updated their recommendations and price targets on shares of Ligand Pharmaceuticals (NASDAQ: LGND) in the last few weeks:

• 5/15/2026 – Ligand Pharmaceuticals was downgraded by Weiss Ratings from “hold (c+)” to “hold (c)”.
• 5/8/2026 – Ligand Pharmaceuticals had its price target raised by Royal Bank Of Canada from $252.00 to $262.00. They now have an “outperform” rating on the stock.
• 5/1/2026 – Ligand Pharmaceuticals was upgraded by Weiss Ratings from “hold (c)” to “hold (c+)”.
• 4/30/2026 – Ligand Pharmaceuticals had its price target raised by HC Wainwright from $243.00 to $289.00. They now have a “buy” rating on the stock.
• 4/28/2026 – Ligand Pharmaceuticals had its price target raised by Royal Bank Of Canada from $235.00 to $252.00. They now have an “outperform” rating on the stock.
• 4/15/2026 – Ligand Pharmaceuticals had its price target raised by Citigroup Inc. from $276.00 to $282.00. They now have a “buy” rating on the stock.
• 4/14/2026 – Ligand Pharmaceuticals had its price target raised by HC Wainwright from $239.00 to $243.00. They now have a “buy” rating on the stock.
• 3/24/2026 – Ligand Pharmaceuticals had its price target raised by Citigroup Inc. from $270.00 to $276.00. They now have a “buy” rating on the stock.

Insider Activity at Ligand Pharmaceuticals

In related news, Director John W. Kozarich sold 1,575 shares of the company’s stock in a transaction that occurred on Wednesday, May 13th. The shares were sold at an average price of $223.50, for a total transaction of $352,012.50. Following the sale, the director directly owned 41,786 shares in the company, valued at approximately $9,339,171. This represents a 3.63% decrease in their position. The sale was disclosed in a filing with the SEC, which can be accessed through this hyperlink. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, insider Andrew Reardon sold 5,000 shares of the company’s stock in a transaction that occurred on Wednesday, March 4th. The shares were sold at an average price of $206.35, for a total transaction of $1,031,750.00. Following the sale, the insider owned 36,869 shares in the company, valued at $7,607,918.15. The trade was a 11.94% decrease in their ownership of the stock. The SEC filing for this sale provides additional information. Insiders have sold 37,949 shares of company stock valued at $8,014,056 in the last three months. Insiders own 7.00% of the company’s stock.

Ligand Pharmaceuticals, Inc is a biopharmaceutical company that acquires, develops and out-licenses proprietary technologies designed to help pharmaceutical and biotechnology companies discover and develop novel medicines. Operating primarily through its research services and royalty-generating businesses, Ligand focuses on building a diversified portfolio of technology platforms and partnering with industry leaders to advance therapeutic candidates across multiple disease areas.

The company’s product offerings center around several core platforms.